Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor — Es-Alert

Duchenne Muscular Dystrophy Clinical Trial

Official title:
Characterization of the Postural Habits of Wheelchair Users in an Ecological Situation and Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor Integrating an Artificial Intelligence Algorithm

Status Completed

Clinical Trial Summary

Spinal cord injuries and people with Duchenne Muscular Dystrophy or Infant Spinal Muscular Atrophy (ISA) are prone to pain and pressure sores associated with prolonged sitting. For this reason, it is recommended that people with spinal cord injuries release pressure every 15 to 30 minutes and motorized wheelchair users use the electric positioning functions at least 1 minute every hour. The aim is to prevent and/or reduce pain and pressure sores. These devices could help to observe daily the variability of users' pressure maps, their impact on occupational performance, the link with pain and redness and could propose customized adjustments.

Clinical Trial Description

The main objective of this study is to evaluate the impact of an algorithm that characterizes the cruro-ischiatic fingerprints used in daily life and that issues an alert in case of detection of a pressure sore risk defined by the literature on the occupational performance of the subjects. The resulting assumption is based on the following points: - The algorithms implemented in this device are able to calculate and isolate a number of cruro-ischiatic fingerprints used during the day during priority activities and active or passive position changes. - They may, in the event of a risk position, issue alerts based on the recommendations. This will allow us to analyze the impact of these alerts on the changes in position and relief actually performed by the subject, analyze the consequences on the MCRO score (psychosocial impact on occupational performance) and verify the impact of visual biofeedback on chair positioning. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04335942
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	N/A
Start date	September 30, 2021
Completion date	June 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05575648` - Dual Task in Duchenne Muscular Dystrophy	N/A
Terminated	`NCT03907072` - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2/Phase 3
Not yet recruiting	`NCT06450639` - An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy	Phase 2
Active, not recruiting	`NCT04906460` - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)	Phase 1/Phase 2
Active, not recruiting	`NCT02500381` - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 3
Enrolling by invitation	`NCT05967351` - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study	Phase 3
Recruiting	`NCT03067831` - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy	Phase 1/Phase 2
Recruiting	`NCT01834040` - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy	Phase 1/Phase 2
Completed	`NCT02246478` - A Study of TAS-205 for Duchenne Muscular Dystrophy	Phase 1
Active, not recruiting	`NCT01772043` - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping	N/A
Terminated	`NCT01168908` - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Phase 2
Completed	`NCT00758225` - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)	Phase 2
Completed	`NCT03680365` - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting	`NCT03513367` - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting	`NCT05712447` - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting	`NCT01484678` - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed	`NCT03319030` - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated	`NCT01753804` - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.	N/A
Completed	`NCT02530905` - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients	Phase 1
Terminated	`NCT04708314` - An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.